Drug Approval | May 19, 2026
FDA expands Enhertu use in early HER2-positive breast cancer
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
NEJM study shows strong protection across strains
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
